The Latest Changes to Nebulizer Medications
In March, the DME Program Safeguard Contractors (DME PSCs) released the following coverage changes in a nebulizer draft LCD:
• Payment for levalbuterol will be based on the allowance for albuterol.
• Payment for DuoNeb will be based on the allowance for separate unit dose vials of albuterol and ipratropium.
• Coverage will be eliminated for the following nebulizer drugs based on inadequate support in the medical literature for administration using a DME nebulizer: amikacin, atropine, beclomethasone, betamethasone, bitolerol, dexamethasone, flunisolide, formoterol, gentamicin, glycopyrrolate, terbutaline and triamcinalone. Coverage will be limited to these drugs: acetylcysteine, albuterol, budesonide, cromolyn, dornase alpha, iloprost, ipratropium, isoetharine, isoproterenol, levalbuterol, metaproterenol, pentamidine and tobramycin.
• Maximum milligrams/month for budesonide were defined.
Related Articles Read More >
1-on-1 With Rob Schlissberg: Scaling Cardinal Health at-Home Solutions’ Footprint in HME
On the AdaptHealth diabetes buyout, expanding distribution, and why he's bullish on the sector's next chapter.
Commentary: Losing Sleep Over Permanent Daylight Saving Time
The U.S. House passed the Sunshine Protection Act this month. Sleep physicians say it’s a bad idea.
Cardinal Health at-Home Solutions Acquires AdaptHealth’s Diabetes Unit and DME Supplier Strive Medical
The two acquisitions cost approximately $360 million in cash.